IKENA ONCOLOGY INC. -

Ikena Oncology Reports Second Quarter 2024 Financial Results

08 Aug 2024 16:15:00 By Nasdaq GlobeNewswire

UPDATE – Ikena Oncology Announces Strategic Update

28 May 2024 16:42:37 By Nasdaq GlobeNewswire

Ikena Oncology Announces Strategic Update

28 May 2024 16:15:00 By Nasdaq GlobeNewswire

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

13 May 2024 16:45:00 By Nasdaq GlobeNewswire

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

10 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

12 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

27 Feb 2024 08:00:01 By Nasdaq GlobeNewswire

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

21 Feb 2024 16:15:00 By Nasdaq GlobeNewswire

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

18 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

09 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

07 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Ikena Oncology to Participate in September 2023 Investor Conferences

05 Sep 2023 08:00:01 By Nasdaq GlobeNewswire

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

10 Aug 2023 08:00:01 By Nasdaq GlobeNewswire

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

07 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Ikena Oncology to Participate in Upcoming Investor Conferences

24 May 2023 08:00:01 By Nasdaq GlobeNewswire

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

15 May 2023 07:50:00 By Nasdaq GlobeNewswire

Ikena Oncology Announces $40 Million Underwritten Offering

15 May 2023 07:45:00 By Nasdaq GlobeNewswire

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

20 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

17 Apr 2023 09:00:01 By Nasdaq GlobeNewswire

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

14 Mar 2023 07:00:00 By Nasdaq GlobeNewswire